51
|
Silva MC, Silva AS, Fernandez-Lodeiro J, Casimiro T, Lodeiro C, Aguiar-Ricardo A. Supercritical CO₂-Assisted Spray Drying of Strawberry-Like Gold-Coated Magnetite Nanocomposites in Chitosan Powders for Inhalation. MATERIALS (BASEL, SWITZERLAND) 2017; 10:E74. [PMID: 28772434 PMCID: PMC5344610 DOI: 10.3390/ma10010074] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Revised: 11/21/2016] [Accepted: 01/11/2017] [Indexed: 01/03/2023]
Abstract
Lung cancer is one of the leading causes of death worldwide. Therefore, it is of extreme importance to develop new systems that can deliver anticancer drugs into the site of action when initiating a treatment. Recently, the use of nanotechnology and particle engineering has enabled the development of new drug delivery platforms for pulmonary delivery. In this work, POXylated strawberry-like gold-coated magnetite nanocomposites and ibuprofen (IBP) were encapsulated into a chitosan matrix using Supercritical Assisted Spray Drying (SASD). The dry powder formulations showed adequate morphology and aerodynamic performances (fine particle fraction 48%-55% and aerodynamic diameter of 2.6-2.8 µm) for deep lung deposition through the pulmonary route. Moreover, the release kinetics of IBP was also investigated showing a faster release of the drug at pH 6.8, the pH of lung cancer. POXylated strawberry-like gold-coated magnetite nanocomposites proved to have suitable sizes for cellular internalization and their fluorescent capabilities enable their future use in in vitro cell based assays. As a proof-of-concept, the reported results show that these nano-in-micro formulations could be potential drug vehicles for pulmonary administration.
Collapse
Affiliation(s)
- Marta C Silva
- LAQV-REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Campus de Caparica, Caparica 2829-516, Portugal.
- BIOSCOPE Research Group, UCIBIO@REQUIMTE, Chemistry Department, Faculty of Science and Technology, University NOVA of Lisbon, Caparica Campus, Caparica 2829-516, Portugal.
| | - Ana Sofia Silva
- LAQV-REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Campus de Caparica, Caparica 2829-516, Portugal.
- CICS-UBI, Health Sciences Research Center, Faculdade de Ciências da Saúde, Universidade da Beira Interior, Av. Infante D. Henrique, Covilhã 6200-506, Portugal.
| | - Javier Fernandez-Lodeiro
- BIOSCOPE Research Group, UCIBIO@REQUIMTE, Chemistry Department, Faculty of Science and Technology, University NOVA of Lisbon, Caparica Campus, Caparica 2829-516, Portugal.
- PROTEOMASS Scientific Society, Rua dos Inventores, Madam Parque, Caparica Campus, Caparica 2829-516, Portugal.
| | - Teresa Casimiro
- LAQV-REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Campus de Caparica, Caparica 2829-516, Portugal.
| | - Carlos Lodeiro
- BIOSCOPE Research Group, UCIBIO@REQUIMTE, Chemistry Department, Faculty of Science and Technology, University NOVA of Lisbon, Caparica Campus, Caparica 2829-516, Portugal.
- PROTEOMASS Scientific Society, Rua dos Inventores, Madam Parque, Caparica Campus, Caparica 2829-516, Portugal.
| | - Ana Aguiar-Ricardo
- LAQV-REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Campus de Caparica, Caparica 2829-516, Portugal.
| |
Collapse
|
52
|
Chouchou A, Aubert-Pouëssel A, Dorandeu C, Zghaib Z, Cuq P, Devoisselle JM, Bonnet PA, Bégu S, Deleuze-Masquefa C. Lipid nanocapsules formulation and cellular activities evaluation of a promising anticancer agent: EAPB0503. Int J Pharm Investig 2017; 7:155-163. [PMID: 29692974 PMCID: PMC5903019 DOI: 10.4103/jphi.jphi_53_17] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Objective: EAPB0503, lead compound of imiqualines, presented high antitumor activities but also a very low water solubility which was critical for further preclinical studies. To apply to EAPB0503, a robust and safe lipid formulation already used for poor soluble anticancer agents for injectable administration at a concentration higher than 1 mg/mL. Materials and Methods: Physicochemical properties of EAPB0503 were determined to consider an adapted formulation. In a second time, lipid nanocapsules (LNC) formulations based on the phase-inversion process were developed for EAPB0503 encapsulation. Then, EAPB0503 loaded-LNC were tested in vitro on different cell lines and compared to standard EAPB0503 solutions. Results: Optimized EAPB0503 LNC displayed an average size of 111.7 ± 0.9 nm and a low polydispersity index of 0.059 ± 0.002. The obtained loading efficiency was higher than 96% with a drug loading of 1.7 mg/mL. A stability study showed stability during 4 weeks stored at 25°C. In vitro results highlighted similar efficiencies between LNC and standard EAPB0503 solutions prepared in dimethyl sulfoxide. Conclusion: In view of results obtained for loading efficiency and drug loading, the use of a LNC formulation is very interesting to permit the solubilization of a lipophilic drug and to improve its bioavailability. Preliminary tested pharmaceutical formulation applied to EAPB0503 significantly improved its water solubility and will be soon considered for future preclinical in vivo studies.
Collapse
Affiliation(s)
- Adrien Chouchou
- CNRS, ENSCM, IBMM, University of Montpellier, Montpellier, France
| | - Anne Aubert-Pouëssel
- UMR 5253, CNRS, ENSCM, University of Montpellier, Institut Charles Gerhardt Montpellier, Montpellier, France
| | - Christophe Dorandeu
- UMR 5253, CNRS, ENSCM, University of Montpellier, Institut Charles Gerhardt Montpellier, Montpellier, France
| | - Zahraa Zghaib
- CNRS, ENSCM, IBMM, University of Montpellier, Montpellier, France
| | - Pierre Cuq
- CNRS, ENSCM, IBMM, University of Montpellier, Montpellier, France
| | - Jean-Marie Devoisselle
- UMR 5253, CNRS, ENSCM, University of Montpellier, Institut Charles Gerhardt Montpellier, Montpellier, France
| | | | - Sylvie Bégu
- UMR 5253, CNRS, ENSCM, University of Montpellier, Institut Charles Gerhardt Montpellier, Montpellier, France
| | | |
Collapse
|
53
|
Shao J, Xie H, Huang H, Li Z, Sun Z, Xu Y, Xiao Q, Yu XF, Zhao Y, Zhang H, Wang H, Chu PK. Biodegradable black phosphorus-based nanospheres for in vivo photothermal cancer therapy. Nat Commun 2016; 7:12967. [PMID: 27686999 PMCID: PMC5056460 DOI: 10.1038/ncomms12967] [Citation(s) in RCA: 576] [Impact Index Per Article: 72.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 08/18/2016] [Indexed: 12/23/2022] Open
Abstract
Photothermal therapy (PTT) offers many advantages such as high efficiency and minimal invasiveness, but clinical adoption of PTT nanoagents have been stifled by unresolved concerns such as the biodegradability as well as long-term toxicity. Herein, poly (lactic-co-glycolic acid) (PLGA) loaded with black phosphorus quantum dots (BPQDs) is processed by an emulsion method to produce biodegradable BPQDs/PLGA nanospheres. The hydrophobic PLGA not only isolates the interior BPQDs from oxygen and water to enhance the photothermal stability, but also control the degradation rate of the BPQDs. The in vitro and in vivo experiments demonstrate that the BPQDs/PLGA nanospheres have inappreciable toxicity and good biocompatibility, and possess excellent PTT efficiency and tumour targeting ability as evidenced by highly efficient tumour ablation under near infrared (NIR) laser illumination. These BP-based nanospheres combine biodegradability and biocompatibility with high PTT efficiency, thus promising high clinical potential.
Collapse
Affiliation(s)
- Jundong Shao
- Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
- SZU-NUS Collaborative Innovation Center for Optoelectronic Science and Technology, and Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China
| | - Hanhan Xie
- Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
| | - Hao Huang
- Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
| | - Zhibin Li
- Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
| | - Zhengbo Sun
- SZU-NUS Collaborative Innovation Center for Optoelectronic Science and Technology, and Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China
| | - Yanhua Xu
- SZU-NUS Collaborative Innovation Center for Optoelectronic Science and Technology, and Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China
| | - Quanlan Xiao
- SZU-NUS Collaborative Innovation Center for Optoelectronic Science and Technology, and Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China
| | - Xue-Feng Yu
- Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
| | - Yuetao Zhao
- Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
| | - Han Zhang
- SZU-NUS Collaborative Innovation Center for Optoelectronic Science and Technology, and Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China
| | - Huaiyu Wang
- Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
| | - Paul K. Chu
- Department of Physics and Materials Science, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong 999077, China
| |
Collapse
|
54
|
Safwat MA, Soliman GM, Sayed D, Attia MA. Gold nanoparticles enhance 5-fluorouracil anticancer efficacy against colorectal cancer cells. Int J Pharm 2016; 513:648-658. [PMID: 27693737 DOI: 10.1016/j.ijpharm.2016.09.076] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Revised: 09/23/2016] [Accepted: 09/28/2016] [Indexed: 01/06/2023]
Abstract
5-Fluorouracil (5-FU), an antimetabolite drug, is extensively used in the treatment solid tumors. However, its severe side effects limit its clinical benefits. To enhance 5-FU anticancer efficacy and reduce its side effects it was loaded onto gold nanoparticles (GNPs) using two thiol containing ligands, thioglycolic acid (TGA) and glutathione (GSH). The GNPs were prepared at different 5-FU/ligand molar ratios and evaluated using different techniques. Anticancer efficacy of 5-FU/GSH-GNPs was studied using flow cytometry in cancerous tissue obtained from patients having colorectal cancer. The GNPs were spherical in shape and had a size of ∼9-17nm. Stability of the GNPs and drug release were studied as a function of salt concentration and solution pH. Maximum 5-FU loading was achieved at 5-FU/ligand molar ratio of 1:1 and 2:1 for TGA-GNPs and GSH-GNPs, respectively. GNPs coating with pluronic F127 improved their stability against salinity. 5-FU release from GNPs was slow and pH-dependent. 5-FU/GSH-GNPs induced apoptosis and stopped the cell cycle progression in colorectal cancer cells. They also had a 2-fold higher anticancer effect compared with free 5-FU. These results confirm the potential of GNPs to enhance 5-FU anticancer efficacy.
Collapse
Affiliation(s)
- Mohamed A Safwat
- Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt; Department of Pharmaceutics and Industrial Pharmacy, Deraya University, El-Minia, Egypt
| | - Ghareb M Soliman
- Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
| | - Douaa Sayed
- Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
| | - Mohamed A Attia
- Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt
| |
Collapse
|
55
|
Polymer Nanoparticles for Cancer Photodynamic Therapy Combined with Nitric Oxide Photorelease and Chemotherapy. ACTA ACUST UNITED AC 2016. [DOI: 10.1007/978-3-319-31671-0_9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
56
|
EGFR targeted thermosensitive liposomes: A novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery. Colloids Surf B Biointerfaces 2016; 146:657-69. [PMID: 27434152 DOI: 10.1016/j.colsurfb.2016.06.012] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Revised: 05/18/2016] [Accepted: 06/08/2016] [Indexed: 01/10/2023]
Abstract
The epidermal growth factor receptor (EGFR) is a promising target for anti-cancer therapy. The aim of this study was to design thermosensitive liposomes (TSL), functionalized with anti-EGFR ligands for targeted delivery and localized triggered release of chemotherapy. For targeting, EGFR specific peptide (GE11) and Fab' fragments of cetuximab were used and the effect of ligand density on in vitro tumor targeting was investigated. Ligand conjugation did not significantly change the physicochemical characteristics of liposomes. Fab'-decorated TSL (Fab'-TSL) can specifically and more efficiently bind to the EGFR overexpressed cancer cells as compared to GE11 modified TSL. Calcein labeled Fab'-TSL showed adequate stability at 37°C in serum (<4% calcein released after 1h) and a temperature dependent release at above 40°C. FACS analysis and live cell imaging showed efficient and EGFR mediated cellular association as well as dramatic intracellular cargo release upon hyperthermia. Fab'-conjugation and hyperthermia induced enhanced tumor cell cytotoxicity of doxorubicin loaded TSL. The relative cytotoxicity of Fab'-TSL was also correlated to EGFR density on the tumor cells. These results suggest that Fab'-TSL showed great potential for combinational targeted and triggered release drug delivery.
Collapse
|
57
|
Dong H, Tang M, Li Y, Li Y, Qian D, Shi D. Disulfide-bridged cleavable PEGylation in polymeric nanomedicine for controlled therapeutic delivery. Nanomedicine (Lond) 2016; 10:1941-58. [PMID: 26139127 DOI: 10.2217/nnm.15.38] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
PEGylation in polymeric nanomedicine has gained substantial predominance in biomedical applications due to its resistance to protein absorption, which is critically important for a therapeutic delivery system in blood circulation. The shielding layer of PEGylation, however, creates significant steric hindrance that negatively impacts cellular uptake and intracellular distribution at the target site. This unexpected effect compromises the biological efficacy of the encapsulated payload. To address this issue, one of the key strategies is to tether the disulfide bond to PEG for constructing a disulfide-bridged cleavable PEGylation. The reversible disulfide bond can be cleaved to enable selective PEG detachment. This article provides an overview on the strategy, method and progress of PEGylation nanosystem with the cleavable disulfide bond.
Collapse
Affiliation(s)
- Haiqing Dong
- Shanghai East Hospital, The Institute for Biomedical Engineering & Nano Science (iNANO), Tongji University School of Medicine, Shanghai, China
| | - Min Tang
- Shanghai East Hospital, The Institute for Biomedical Engineering & Nano Science (iNANO), Tongji University School of Medicine, Shanghai, China
| | - Yan Li
- Shanghai East Hospital, The Institute for Biomedical Engineering & Nano Science (iNANO), Tongji University School of Medicine, Shanghai, China
| | - Yongyong Li
- Shanghai East Hospital, The Institute for Biomedical Engineering & Nano Science (iNANO), Tongji University School of Medicine, Shanghai, China
| | - Dong Qian
- Department of Mechanical Engineering, University of Texas at Dallas, TX 75080, USA
| | - Donglu Shi
- Shanghai East Hospital, The Institute for Biomedical Engineering & Nano Science (iNANO), Tongji University School of Medicine, Shanghai, China.,The Materials Science & Engineering Program, Department of Mechanical & Materials Engineering, College of Engineering & Applied Science, University of Cincinnati, Cincinnati, OH 45221, USA
| |
Collapse
|
58
|
Kim J, Kim J, Jeong C, Kim WJ. Synergistic nanomedicine by combined gene and photothermal therapy. Adv Drug Deliv Rev 2016; 98:99-112. [PMID: 26748259 DOI: 10.1016/j.addr.2015.12.018] [Citation(s) in RCA: 170] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2015] [Revised: 12/20/2015] [Accepted: 12/22/2015] [Indexed: 12/19/2022]
Abstract
To date, various nanomaterials with the ability for gene delivery or photothermal effect have been developed in the field of biomedicine. The therapeutic potential of these nanomaterials has raised considerable interests in their use in potential next-generation strategies for effective anticancer therapy. In particular, the advancement of novel nanomedicines utilizing both therapeutic strategies of gene delivery and photothermal effect has generated much optimism regarding the imminent development of effective and successful cancer treatments. In this review, we discuss current research progress with regard to combined gene and photothermal therapy. This review focuses on synergistic therapeutic systems combining gene regulation and photothermal ablation as well as logically designed nano-carriers aimed at enhancing the delivery efficiency of therapeutic genes using the photothermal effect. The examples detailed in this review provide insight to further our understanding of combinatorial gene and photothermal therapy, thus paving the way for the design of promising nanomedicines.
Collapse
|
59
|
Abstract
In chemotherapy a fine balance between therapeutic and toxic effects needs to be found for each patient, adapting standard combination protocols each time. Nanotherapeutics has been introduced into clinical practice for treating tumors with the aim of improving the therapeutic outcome of conventional therapies and of alleviating their toxicity and overcoming multidrug resistance. Photodynamic therapy (PDT) is a clinically approved, minimally invasive procedure emerging in cancer treatment. It involves the administration of a photosensitizer (PS) which, under light irradiation and in the presence of molecular oxygen, produces cytotoxic species. Unfortunately, most PSs lack specificity for tumor cells and are poorly soluble in aqueous media, where they can form aggregates with low photoactivity. Nanotechnological approaches in PDT (nanoPDT) can offer a valid option to deliver PSs in the body and to solve at least some of these issues. Currently, polymeric nanoparticles (NPs) are emerging as nanoPDT system because their features (size, surface properties, and release rate) can be readily manipulated by selecting appropriate materials in a vast range of possible candidates commercially available and by synthesizing novel tailor-made materials. Delivery of PSs through NPs offers a great opportunity to overcome PDT drawbacks based on the concept that a nanocarrier can drive therapeutic concentrations of PS to the tumor cells without generating any harmful effect in non-target tissues. Furthermore, carriers for nanoPDT can surmount solubility issues and the tendency of PS to aggregate, which can severely affect photophysical, chemical, and biological properties. Finally, multimodal NPs carrying different drugs/bioactive species with complementary mechanisms of cancer cell killing and incorporating an imaging agent can be developed. In the following, we describe the principles of PDT use in cancer and the pillars of rational design of nanoPDT carriers dictated by tumor and PS features. Then we illustrate the main nanoPDT systems demonstrating potential in preclinical models together with emerging concepts for their advanced design.
Collapse
|
60
|
Pham BTT, Jain N, Kuchel PW, Chapman BE, Bickley SA, Jones SK, Hawkett BS. The interaction of sterically stabilized magnetic nanoparticles with fresh human red blood cells. Int J Nanomedicine 2015; 10:6645-55. [PMID: 26604741 PMCID: PMC4629969 DOI: 10.2147/ijn.s93225] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Sterically stabilized superparamagnetic iron oxide nanoparticles (SPIONs) were incubated with fresh human erythrocytes (red blood cells [RBCs]) to explore their potential application as magnetic resonance imaging contrast agents. The chemical shift and linewidth of (133)Cs(+) resonances from inside and outside the RBCs in (133)Cs nuclear magnetic resonance spectra were monitored as a function of time. Thus, we investigated whether SPIONs of two different core sizes and with three different types of polymeric stabilizers entered metabolically active RBCs, consuming glucose at 37°C. The SPIONs broadened the extracellular (133)Cs(+) nuclear magnetic resonance, and brought about a small change in its chemical shift to a higher frequency; while the intracellular resonance remained unchanged in both amplitude and chemical shift. This situation pertained over incubation times of up to 90 minutes. If the SPIONs had entered the RBCs, the intracellular resonance would have become broader and possibly even shifted. Therefore, we concluded that our SPIONs did not enter the RBCs. In addition, the T 2 relaxivity of the small and large particles was 368 and 953 mM(-1) s(-1), respectively (three and nine times that of the most effective commercially available samples). This suggests that these new SPIONs will provide a superior performance to any others reported thus far as magnetic resonance imaging contrast agents.
Collapse
Affiliation(s)
- Binh TT Pham
- School of Chemistry, University of Sydney, NSW, Australia
| | - Nirmesh Jain
- School of Chemistry, University of Sydney, NSW, Australia
| | - Philip W Kuchel
- School of Molecular Bioscience, University of Sydney, NSW, Australia
| | - Bogdan E Chapman
- School of Molecular Bioscience, University of Sydney, NSW, Australia
| | | | | | | |
Collapse
|
61
|
Sobczynski DJ, Fish MB, Fromen CA, Carasco-Teja M, Coleman RM, Eniola-Adefeso O. Drug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted drug delivery systems. Ther Deliv 2015; 6:915-34. [PMID: 26272334 PMCID: PMC4618056 DOI: 10.4155/tde.15.38] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Vascular wall endothelial cells control several physiological processes and are implicated in many diseases, making them an attractive candidate for drug targeting. Vascular-targeted drug carriers (VTCs) offer potential for reduced side effects and improved therapeutic efficacy, however, only limited therapeutic success has been achieved to date. This is perhaps due to complex interactions of VTCs with blood components, which dictate VTC transport and adhesion to endothelial cells. This review focuses on VTC interaction with blood as well as novel 'bio-inspired' designs to mimic and exploit features of blood in VTC development. Advanced approaches for enhancing VTCs are discussed along with applications in regenerative medicine, an area of massive potential growth and expansion of VTC utility in the near future.
Collapse
Affiliation(s)
- Daniel J Sobczynski
- Department of Chemical Engineering, University of Michigan, Ann Arbor MI, USA 48109
| | - Margaret B Fish
- Department of Chemical Engineering, University of Michigan, Ann Arbor MI, USA 48109
| | - Catherine A Fromen
- Department of Chemical Engineering, University of Michigan, Ann Arbor MI, USA 48109
| | - Mariana Carasco-Teja
- Department of Chemical Engineering, University of Michigan, Ann Arbor MI, USA 48109
| | - Rhima M Coleman
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA 48109
| | - Omolola Eniola-Adefeso
- Department of Chemical Engineering, University of Michigan, Ann Arbor MI, USA 48109
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA 48109
| |
Collapse
|
62
|
Niedermayer S, Weiss V, Herrmann A, Schmidt A, Datz S, Müller K, Wagner E, Bein T, Bräuchle C. Multifunctional polymer-capped mesoporous silica nanoparticles for pH-responsive targeted drug delivery. NANOSCALE 2015; 7:7953-7964. [PMID: 25865957 DOI: 10.1039/c4nr07245f] [Citation(s) in RCA: 101] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
A highly stable modular platform, based on the sequential covalent attachment of different functionalities to the surface of core-shell mesoporous silica nanoparticles (MSNs) for targeted drug delivery is presented. A reversible pH-responsive cap system based on covalently attached poly(2-vinylpyridine) (PVP) was developed as drug release mechanism. Our platform offers (i) tuneable interactions and release kinetics with the cargo drug in the mesopores based on chemically orthogonal core-shell design, (ii) an extremely robust and reversible closure and release mechanism based on endosomal acidification of the covalently attached PVP polymer block, (iii) high colloidal stability due to a covalently coupled PEG shell, and (iv) the ability to covalently attach a wide variety of dyes, targeting ligands and other functionalities at the outer periphery of the PEG shell. The functionality of the system was demonstrated in several cell studies, showing pH-triggered release in the endosome, light-triggered endosomal escape with an on-board photosensitizer, and efficient folic acid-based cell targeting.
Collapse
Affiliation(s)
- Stefan Niedermayer
- Department of Chemistry, Nanosystems Initiative Munich (NIM) and Center for Nano Science (CeNS), University of Munich (LMU), Butenandtstr. 11 (E), 81377 Munich, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
63
|
Zwitterionic polymeric micelles that undergo a pH-triggered positive charge for enhanced cellular uptake. Eur Polym J 2015. [DOI: 10.1016/j.eurpolymj.2015.02.041] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
64
|
Fabrication and Characterization of Gd-DTPA-Loaded Chitosan-Poly(Acrylic Acid) Nanoparticles for Magnetic Resonance Imaging. Macromol Biosci 2015; 15:1105-14. [DOI: 10.1002/mabi.201500034] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2015] [Revised: 03/11/2015] [Indexed: 11/07/2022]
|
65
|
Lollo G, Hervella P, Calvo P, Avilés P, Guillén MJ, Garcia-Fuentes M, Alonso MJ, Torres D. Enhanced in vivo therapeutic efficacy of plitidepsin-loaded nanocapsules decorated with a new poly-aminoacid-PEG derivative. Int J Pharm 2015; 483:212-9. [DOI: 10.1016/j.ijpharm.2015.02.028] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Revised: 02/08/2015] [Accepted: 02/10/2015] [Indexed: 12/15/2022]
|
66
|
Maiolino S, Moret F, Conte C, Fraix A, Tirino P, Ungaro F, Sortino S, Reddi E, Quaglia F. Hyaluronan-decorated polymer nanoparticles targeting the CD44 receptor for the combined photo/chemo-therapy of cancer. NANOSCALE 2015; 7:5643-5653. [PMID: 25648974 DOI: 10.1039/c4nr06910b] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
In the attempt to develop novel concepts in designing targeted nanoparticles for combination therapy of cancer, we propose here CD44-targeted hyaluronan-decorated double-coated nanoparticles (dcNPs) delivering the lipophilic chemotherapeutic docetaxel (DTX) and an anionic porphyrin (TPPS₄). dcNPs are based on electrostatic interactions between a negative DTX-loaded nanoscaffold of poly(lactide-co-glycolide), a polycationic shell of polyethyleneimine entangling negatively-charged TPPS₄ and finally decorated with hyaluronan (HA) to promote internalization through CD44 receptor-mediated endocytosis. DTX/TPPS₄-dcNPs, prepared through layer-by-layer deposition, showed a hydrodynamic diameter of around 180 nm, negative zeta potential and efficient loading of both DTX and TPPS₄. DTX/TPPS₄-dcNPs were freeze-dried with trehalose giving a powder that could be easily dispersed in different media. Excellent stability of dcNPs in specific salt- and protein-containing media was found. Spectroscopic behavior of DTX/TPPS₄-dcNPs demonstrated a face-to-face arrangement of the TPPS₄ units in non-photoresponsive H-type aggregates accounting for an extensive aggregation of the porphyrin embedded in the shell. Experiments in MDA-MB-231 cells overexpressing the CD44 receptor demonstrated a 9.4-fold increase in the intracellular level of TPPS₄ delivered from dcNPs as compared to free TPPS₄. Light-induced death increased tremendously in cells that had been treated with a combination of TPPS₄ and DTX delivered through dcNPs as compared with free drugs, presumably due to efficient uptake and co-localization inside the cells. In perspective, the strategy proposed here to target synergistic drug combinations through HA-decorated nanoparticles seems very attractive to improve the specificity and efficacy of cancer treatment.
Collapse
Affiliation(s)
- Sara Maiolino
- Drug Delivery Laboratory, Department of Pharmacy, University of Napoli Federico II, Via Domenico Montesano 49, 80131, Napoli, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
67
|
Self-assembled biotransesterified cyclodextrins as potential Artemisinin nanocarriers. II: In vitro behavior toward the immune system and in vivo biodistribution assessment of unloaded nanoparticles. Eur J Pharm Biopharm 2014; 88:683-94. [DOI: 10.1016/j.ejpb.2014.08.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2014] [Revised: 08/21/2014] [Accepted: 08/25/2014] [Indexed: 01/24/2023]
|
68
|
Dawidczyk CM, Russell LM, Searson PC. Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. Front Chem 2014; 2:69. [PMID: 25202689 PMCID: PMC4142601 DOI: 10.3389/fchem.2014.00069] [Citation(s) in RCA: 91] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2014] [Accepted: 08/05/2014] [Indexed: 01/31/2023] Open
Abstract
The ability to efficiently deliver a drug or gene to a tumor site is dependent on a wide range of factors including circulation time, interactions with the mononuclear phagocyte system, extravasation from circulation at the tumor site, targeting strategy, release from the delivery vehicle, and uptake in cancer cells. Nanotechnology provides the possibility of creating delivery systems where the design constraints are decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing tumor accumulation, and improving efficacy. The physico-chemical properties of nanoparticle-based delivery platforms introduce additional complexity associated with pharmacokinetics, tumor accumulation, and biodistribution. To assess the impact of nanoparticle-based delivery systems, we first review the design strategies and pharmacokinetics of FDA-approved nanomedicines. Next we review nanomedicines under development, summarizing the range of nanoparticle platforms, strategies for targeting, and pharmacokinetics. We show how the lack of uniformity in preclinical trials prevents systematic comparison and hence limits advances in the field.
Collapse
Affiliation(s)
- Charlene M Dawidczyk
- Institute for Nanobiotechnology, Johns Hopkins University Baltimore, MD, USA ; Johns Hopkins Center of Cancer Nanotechnology Excellence, Johns Hopkins University Baltimore, MD, USA ; Department of Materials Science and Engineering, Johns Hopkins University Baltimore, MD, USA
| | - Luisa M Russell
- Institute for Nanobiotechnology, Johns Hopkins University Baltimore, MD, USA ; Johns Hopkins Center of Cancer Nanotechnology Excellence, Johns Hopkins University Baltimore, MD, USA ; Department of Materials Science and Engineering, Johns Hopkins University Baltimore, MD, USA
| | - Peter C Searson
- Institute for Nanobiotechnology, Johns Hopkins University Baltimore, MD, USA ; Johns Hopkins Center of Cancer Nanotechnology Excellence, Johns Hopkins University Baltimore, MD, USA ; Department of Materials Science and Engineering, Johns Hopkins University Baltimore, MD, USA
| |
Collapse
|
69
|
Bazak R, Houri M, Achy SE, Hussein W, Refaat T. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Mol Clin Oncol 2014; 2:904-908. [PMID: 25279172 DOI: 10.3892/mco.2014.356] [Citation(s) in RCA: 187] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Accepted: 07/02/2014] [Indexed: 12/21/2022] Open
Abstract
Cancer remains the one of the most common causes of mortality in humans; thus, cancer treatment is currently a major focus of investigation. Researchers worldwide have been searching for the optimal treatment (the 'magic bullet') that will selectively target cancer, without afflicting significant morbidity. Recent advances in cancer nanotechnology have raised exciting opportunities for specific drug delivery by an emerging class of nanotherapeutics that may be targeted to neoplastic cells, thereby offering a major advantage over conventional chemotherapeutic agents. There are two ways by which targeting of nanoparticles may be achieved, namely passive and active targeting. The aim of this study was to provide a comprehensive review of the literature focusing on passive targeting.
Collapse
Affiliation(s)
- Remon Bazak
- Department of Otorhinolaryngology, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt
| | - Mohamad Houri
- Department of Ophthalmology, Faculty of Medicine, Beirut Arab University, Beirut 1107 2809, Lebanon
| | - Samar El Achy
- Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt
| | - Wael Hussein
- Department of Otorhinolaryngology, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt
| | - Tamer Refaat
- Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt ; Department of Radiation Oncology, Northwestern University, Chicago, IL 60611, USA
| |
Collapse
|
70
|
Zarschler K, Prapainop K, Mahon E, Rocks L, Bramini M, Kelly PM, Stephan H, Dawson KA. Diagnostic nanoparticle targeting of the EGF-receptor in complex biological conditions using single-domain antibodies. NANOSCALE 2014; 6:6046-6056. [PMID: 24777583 DOI: 10.1039/c4nr00595c] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
For effective localization of functionalized nanoparticles at diseased tissues such as solid tumours or metastases through biorecognition, appropriate targeting vectors directed against selected tumour biomarkers are a key prerequisite. The diversity of such vector molecules ranges from proteins, including antibodies and fragments thereof, through aptamers and glycans to short peptides and small molecules. Here, we analyse the specific nanoparticle targeting capabilities of two previously suggested peptides (D4 and GE11) and a small camelid single-domain antibody (sdAb), representing potential recognition agents for the epidermal growth factor receptor (EGFR). We investigate specificity by way of receptor RNA silencing techniques and look at increasing complexity in vitro by introducing increasing concentrations of human or bovine serum. Peptides D4 and GE11 proved problematic to employ and conjugation resulted in non-receptor specific uptake into cells. Our results show that sdAb-functionalized particles can effectively target the EGFR, even in more complex bovine and human serum conditions where targeting specificity is largely conserved for increasing serum concentration. In human serum however, an inhibition of overall nanoparticle uptake is observed with increasing protein concentration. For highly affine targeting ligands such as sdAbs, targeting a receptor such as EGFR with low serum competitor abundance, receptor recognition function can still be partially realised in complex conditions. Here, we stress the value of evaluating the targeting efficiency of nanoparticle constructs in realistic biological milieu, prior to more extensive in vivo studies.
Collapse
Affiliation(s)
- K Zarschler
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, D-01328 Dresden, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
71
|
Lainé AL, Clavreul A, Rousseau A, Tétaud C, Vessieres A, Garcion E, Jaouen G, Aubert L, Guilbert M, Benoit JP, Toillon RA, Passirani C. Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2014; 10:1667-77. [PMID: 24842766 DOI: 10.1016/j.nano.2014.05.002] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/12/2013] [Revised: 03/28/2014] [Accepted: 05/03/2014] [Indexed: 10/25/2022]
Abstract
UNLABELLED In this work, a novel ferrocenyl complex (ansa-FcdiOH) was assessed for brain tumor therapy through stealth lipid nanocapsules (LNCs). Stealth LNCs, prepared according to a one-step process, showed rapid uptake by cancer cells and extended blood circulation time. The ferrocenyl complex was successfully encapsulated into these LNCs measuring 40 nm with a high loading capacity (6.4%). In vitro studies showed a potent anticancer effect of ansa-FcdiOH on 9L cells with a low IC50 value (0.1 μM) associated with an oxidative stress and a dose-dependent alteration of the cell cycle. Repeated intravenous injections of stealth ansa-FcdiOH LNCs in ectopic glioma bearing rats induced a significant tumor growth inhibition, supported by a reduced number of proliferative cells in tumors compared to control group. Additionally, no liver damage was observed in treated animals. These results indicated that stealth ansa-FcdiOH LNCs might be considered as a potential new approach for cancer chemotherapy. FROM THE CLINICAL EDITOR In this study, a novel ferrocenyl complex was assessed for brain tumor therapy through stealth lipid nanocapsules, demonstrating no liver damage, and superior tumor volume reduction compared to saline and stealth lipid nanocapsules alone in an ectopic glioma model.
Collapse
Affiliation(s)
- Anne-Laure Lainé
- LUNAM Université - Micro et Nanomédecines Biomimétiques, Angers, France; Inserm U1066, IBS-CHU, Angers, France
| | - Anne Clavreul
- Inserm U1066, IBS-CHU, Angers, France; Département de Neurochirurgie - CHU, Angers, France
| | - Audrey Rousseau
- Département de Pathologie Cellulaire et Tissulaire - CHU, Angers, France
| | - Clément Tétaud
- Inserm U1066, IBS-CHU, Angers, France; Département de Neurochirurgie - CHU, Angers, France
| | | | - Emmanuel Garcion
- LUNAM Université - Micro et Nanomédecines Biomimétiques, Angers, France; Inserm U1066, IBS-CHU, Angers, France
| | | | - Léo Aubert
- Inserm U908, Université Lille 1, Villeneuve d'Ascq, France
| | | | - Jean-Pierre Benoit
- LUNAM Université - Micro et Nanomédecines Biomimétiques, Angers, France; Inserm U1066, IBS-CHU, Angers, France
| | | | - Catherine Passirani
- LUNAM Université - Micro et Nanomédecines Biomimétiques, Angers, France; Inserm U1066, IBS-CHU, Angers, France.
| |
Collapse
|
72
|
Zhang Y, Wang C, Xu C, Yang C, Zhang Z, Yan H, Liu K. Morpholino-decorated long circulating polymeric micelles with the function of surface charge transition triggered by pH changes. Chem Commun (Camb) 2014; 49:7286-8. [PMID: 23846234 DOI: 10.1039/c3cc43334j] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Micelles with surface morpholino groups were stealthy at blood and normal tissue pH (7.4) due to the unprotonated hydrophilic morpholino groups on the surfaces. At tumor pH (<7), the micelle surfaces were positively charged because of the protonation of the morpholino groups, which promoted the cellular uptake of the micelles.
Collapse
Affiliation(s)
- Yan Zhang
- Key Laboratory of Functional Polymer Materials (Ministry of Education), Institute of Polymer Chemistry, Nankai University, Tianjin 300071, China
| | | | | | | | | | | | | |
Collapse
|
73
|
Rolfe BE, Blakey I, Squires O, Peng H, Boase NRB, Alexander C, Parsons PG, Boyle GM, Whittaker AK, Thurecht KJ. Multimodal Polymer Nanoparticles with Combined 19F Magnetic Resonance and Optical Detection for Tunable, Targeted, Multimodal Imaging in Vivo. J Am Chem Soc 2014; 136:2413-9. [DOI: 10.1021/ja410351h] [Citation(s) in RCA: 142] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
| | | | | | | | | | - Cameron Alexander
- School
of Pharmacy, The University of Nottingham, Nottingham NG7 2RD, United Kingdom
| | - Peter G. Parsons
- Queensland
Institute for Medical Research, The Royal Brisbane Hospital, Herston, Queensland 4006, Australia
| | - Glen M. Boyle
- Queensland
Institute for Medical Research, The Royal Brisbane Hospital, Herston, Queensland 4006, Australia
| | | | | |
Collapse
|
74
|
A new potential nano-oncological therapy based on polyamino acid nanocapsules. J Control Release 2014; 169:10-6. [PMID: 23591661 DOI: 10.1016/j.jconrel.2013.03.037] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2012] [Revised: 03/09/2013] [Accepted: 03/18/2013] [Indexed: 11/20/2022]
Abstract
A critical objective in cancer therapy is to reduce the systemic toxicity through the modification of the biodistribution of anticancer drugs. Herein, we disclose a new biodegradable nanocarrier, polyglutamic acid (PGA) nanocapsules, and present the in vivo pharmacokinetics/toxicity proof-of-concept for the anticancer drug plitidepsin. These novel nanocapsules were prepared using a modified solvent displacement technique where the polyamino acid was electrostatically deposited onto the lipid core. The nanocapsules exhibited an average size of 200 nm, a negative zeta potential and a great capacity for the encapsulation of plitidepsin (encapsulation efficiency above 90%). In addition, the nanocapsules could be freeze-dried and showed an adequate stability profile upon storage. Finally, the in vivo proof-of-concept studies performed in mice indicated that the encapsulation provided the drug with a prolonged blood circulation and a significantly reduced toxicity. In fact, the maximum tolerated dose of the nanoencapsulated drug was more than 3 times that of the reference formulation (Cremophor® EL plitidepsin solution). Overall, beyond the value of this specific formulation, the work reported here represents the evidence of the potential of polyamino acid nanocapsules in nano-oncological therapy.
Collapse
|
75
|
Conte C, Ungaro F, Mazzaglia A, Quaglia F. Photodynamic Therapy for Cancer: Principles, Clinical Applications, and Nanotechnological Approaches. NANO-ONCOLOGICALS 2014. [DOI: 10.1007/978-3-319-08084-0_5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
|
76
|
Nanomedicine: The Promise and Challenges in Cancer Chemotherapy. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2014; 811:207-33. [DOI: 10.1007/978-94-017-8739-0_11] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
77
|
Valencia PM, Pridgen EM, Rhee M, Langer R, Farokhzad OC, Karnik R. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS NANO 2013; 7:10671-80. [PMID: 24215426 PMCID: PMC3963607 DOI: 10.1021/nn403370e] [Citation(s) in RCA: 142] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Abstract
Taking a nanoparticle (NP) from discovery to clinical translation has been slow compared to small molecules, in part by the lack of systems that enable their precise engineering and rapid optimization. In this work we have developed a microfluidic platform for the rapid, combinatorial synthesis and optimization of NPs. The system takes in a number of NP precursors from which a library of NPs with varying size, surface charge, target ligand density, and drug load is produced in a reproducible manner. We rapidly synthesized 45 different formulations of poly(lactic-co-glycolic acid)-b-poly(ethylene glycol) NPs of different size and surface composition and screened and ranked the NPs for their ability to evade macrophage uptake in vitro. Comparison of the results to pharmacokinetic studies in vivo in mice revealed a correlation between in vitro screen and in vivo behavior. Next, we selected NP synthesis parameters that resulted in longer blood half-life and used the microfluidic platform to synthesize targeted NPs with varying targeting ligand density (using a model targeting ligand against cancer cells). We screened NPs in vitro against prostate cancer cells as well as macrophages, identifying one formulation that exhibited high uptake by cancer cells yet similar macrophage uptake compared to nontargeted NPs. In vivo, the selected targeted NPs showed a 3.5-fold increase in tumor accumulation in mice compared to nontargeted NPs. The developed microfluidic platform in this work represents a tool that could potentially accelerate the discovery and clinical translation of NPs.
Collapse
Affiliation(s)
- Pedro M. Valencia
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Eric M. Pridgen
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Minsoung Rhee
- Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Robert Langer
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139
- MIT-Harvard Center for Cancer Nanotechnology Excellence, Massachusetts Institute of Technology, Cambridge, MA 02139
- To whom correspondence should be addressed. Omid C. Farokhzad Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115. ; Rohit Karnik Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139. ; Robert Langer Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Omid C. Farokhzad
- Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115
- MIT-Harvard Center for Cancer Nanotechnology Excellence, Massachusetts Institute of Technology, Cambridge, MA 02139
- To whom correspondence should be addressed. Omid C. Farokhzad Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115. ; Rohit Karnik Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139. ; Robert Langer Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Rohit Karnik
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139
- To whom correspondence should be addressed. Omid C. Farokhzad Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115. ; Rohit Karnik Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139. ; Robert Langer Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139
| |
Collapse
|
78
|
Rivera-Rodriguez GR, Lollo G, Montier T, Benoit JP, Passirani C, Alonso MJ, Torres D. In vivo evaluation of poly-l-asparagine nanocapsules as carriers for anti-cancer drug delivery. Int J Pharm 2013; 458:83-9. [DOI: 10.1016/j.ijpharm.2013.09.038] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2013] [Revised: 09/26/2013] [Accepted: 09/29/2013] [Indexed: 12/18/2022]
|
79
|
Controlling the actuation of therapeutic nanomaterials: enabling nanoparticle-mediated drug delivery. Ther Deliv 2013; 4:1411-29. [DOI: 10.4155/tde.13.110] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
The implementation of biofunctionalized nanoparticles (NPs) as potential therapeutic materials has seen exponential growth in recent years due to their unique ability to overcome the constraints of current medicine. This has been largely driven by significant advances on a number of basic research fronts including high-quality NP synthesis, bioconjugation, cellular delivery and the controlled release or ‘actuation’ of NP-associated cargos. Cumulatively, these are the key enabling tools for the full realization of NP-mediated drug delivery. In this review, the authors’ focus is on recent developments in methodologies for the controlled actuation of therapeutic NPs. The authors discuss the critical requirements for their integration into biological systems and highlight examples from the recent literature where controlled NP actuation has been successfully demonstrated. The current state of therapeutic NPs in the clinical setting is summarized and the article concludes with a brief perspective of how we can expect to see this emerging field develop in the coming years.
Collapse
|
80
|
Cui ZK, Lafleur M. Lamellar self-assemblies of single-chain amphiphiles and sterols and their derived liposomes: distinct compositions and distinct properties. Colloids Surf B Biointerfaces 2013; 114:177-85. [PMID: 24184913 DOI: 10.1016/j.colsurfb.2013.09.042] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2013] [Revised: 09/16/2013] [Accepted: 09/18/2013] [Indexed: 11/17/2022]
Abstract
Typically, single-chain amphiphiles and sterols do not form fluid lamellar phases once hydrated individually. Most of the single-chain amphiphiles form actually micelles in aqueous environments, while sterols display a very limited solubility in water. However, under certain conditions, mixtures of single-chain amphiphiles and sterols lead to the formation of stable fluid bilayers. Over the past decade, several of these systems leading to fluid lamellar self-assemblies have been identified and this article reviews the current knowledge relative to these non-phospholipid bilayers made of single-chain amphiphiles and sterols. It presents an integrated view about the molecular features that are required for their stability, the properties they share, and the origin of these characteristics. It was also shown that these lamellar systems could lead to the formation of unilamellar vesicles, similar to phospholipid based liposomes. These vesicles display distinct properties that make them potentially appealing for technological applications; they display a limited permeability, they are stable, they are formed with molecules that are relatively chemically inert (and relatively cheap), and they can be readily functionalized. The features of these distinct liposomes and their technological applications are reviewed. Finally, the putative biological implications of these non-phospholipid fluid bilayers are also discussed.
Collapse
Affiliation(s)
- Zhong-Kai Cui
- Department of Chemistry, Center for Self-Assembled Chemical Structures (CSACS), Université de Montréal, C.P. 6128, Succ. Centre Ville, Montréal, Québec H3C 3J7, Canada
| | - Michel Lafleur
- Department of Chemistry, Center for Self-Assembled Chemical Structures (CSACS), Université de Montréal, C.P. 6128, Succ. Centre Ville, Montréal, Québec H3C 3J7, Canada.
| |
Collapse
|
81
|
David S, Marchais H, Hervé-Aubert K, Bedin D, Garin AS, Hoinard C, Chourpa I. Use of experimental design methodology for the development of new magnetic siRNA nanovectors (MSN). Int J Pharm 2013; 454:660-7. [DOI: 10.1016/j.ijpharm.2013.05.051] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2013] [Revised: 05/17/2013] [Accepted: 05/19/2013] [Indexed: 10/26/2022]
|
82
|
Ahmed E, Morton SW, Hammond PT, Swager TM. Fluorescent multiblock π-conjugated polymer nanoparticles for in vivo tumor targeting. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2013; 25:4504-10. [PMID: 23794490 PMCID: PMC4001254 DOI: 10.1002/adma.201301656] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/13/2013] [Revised: 05/16/2013] [Indexed: 05/19/2023]
Abstract
Highly fluorescent multiblock conjugated polymer nanoparticles with folic acid surface ligands are highly effective for bioimaging and in vivo tumor targeting. The targeted nanoparticles were preferentially localized in tumor cells in vivo, thereby illustrating their potential for diagnostic and therapeutic applications.
Collapse
Affiliation(s)
- Eilaf Ahmed
- Department of Chemistry and Institute for Soldier Nanotechnologies, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139 (USA)
| | - Stephen W. Morton
- Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139 (USA)
| | - Paula T. Hammond
- Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139 (USA)
| | - Timothy M. Swager
- Department of Chemistry and Institute for Soldier Nanotechnologies, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139 (USA)
| |
Collapse
|
83
|
Bryce NS, Pham BTT, Fong NWS, Jain N, Pan EH, Whan RM, Hambley TW, Hawkett BS. The composition and end-group functionality of sterically stabilized nanoparticles enhances the effectiveness of co-administered cytotoxins. Biomater Sci 2013; 1:1260-1272. [DOI: 10.1039/c3bm60120j] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
84
|
Formation of artificial multicompartment vesosome and dendrosome as prospected drug and gene delivery carriers. J Control Release 2013; 170:141-52. [DOI: 10.1016/j.jconrel.2013.05.011] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2013] [Revised: 05/15/2013] [Accepted: 05/16/2013] [Indexed: 12/11/2022]
|
85
|
Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide. Eur J Pharm Sci 2013; 50:172-80. [PMID: 23831519 DOI: 10.1016/j.ejps.2013.06.013] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2013] [Revised: 06/11/2013] [Accepted: 06/25/2013] [Indexed: 12/25/2022]
Abstract
Small cell lung cancer (SCLC) is the most aggressive carcinoma in thoracic oncology, unfortunately, despite chemotherapy, relapse is constant. The effect of etoposide, a major drug used against SCLC, can potentially be enhanced after its encapsulation in nanocarriers. The aim of this study was to use the technology of lipid nanocapsules (LNCs) to obtain nanocarriers with drug loadings compatible with clinical use and with an industrial process. Solubility studies with different co-solvent were first performed, then several process were developed to obtain LNCs. LNCs were then characterized (size, zeta potential, and drug loading). The best formulation called Ω-LNCs had a size of 54.1±2.0 nm and a zeta potential of -5.8±3.5 mV and a etoposide drug loading of 5.7±0.3mg/g. The characteristics of this formulation were maintained after freeze drying and after a 15× scale-up. Release studies in a media mimicking plasma composition showed that 40% of the drug was released from the LNCs after 48 h. Moreover the activity of etoposide after encapsulation was enhanced on H209 cells, IC50 was 100 μM and 2.5 μM for etoposide and etoposide LNCs respectively. Unfortunately the formulation failed to be more cytotoxic than etoposide alone on H69AR cells that are resistant to etoposide. This study showed that is was possible to obtain a new etoposide nanocarrier without the use of organic solvent, that the process is suitable for scale-up and freeze drying and finally that etoposide activity is maintained which is very promising for future treatment of SCLC.
Collapse
|
86
|
David S, Montier T, Carmoy N, Resnier P, Clavreul A, Mével M, Pitard B, Benoit JP, Passirani C. Treatment efficacy of DNA lipid nanocapsules and DNA multimodular systems after systemic administration in a human glioma model. J Gene Med 2013; 14:769-75. [PMID: 23143656 DOI: 10.1002/jgm.2683] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2012] [Revised: 07/15/2012] [Accepted: 11/05/2012] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND We previously developed different types of DNA nanocarriers for systemic administration. Recently, the biodistribution profiles of these intravenously administered nanocarriers, DNA lipid nanocapsules (LNCs) and different multimodular systems (MMS), were analysed in healthy mice using in vivo biofluorescence imaging. METHODS In the present study, the experiments were performed in an ectopic human U87MG glioma model in nude mice. First, the biodistribution profiles of intravenously administered multimodular systems delivering a plasmid DNA with a luciferase cassette were analysed using in vivo biofluorescence imaging. Afterwards, a systemic treatment with two long circulating DNA nanocarriers, poly(ethylene glycol) (PEG) DNA LNCs and galactose (GAL) DNA MMS dioleylamin-succinyl paromomycin (DOSP) was performed on this glioma model using a plasmid encoding the herpes simplex virus thymidine kinase (HSV-tk) and subsequent ganciclovir (GCV) treatment. RESULTS The biodistribution profiles of the different DNA nanocarriers on this glioma model were similar to those observed on healthy animals and varied in function of their cationic lipid composition and their surface characteristics. Furthermore, PEG DNA LNCs and GAL DNA MMS DOSP showed a specific accumulation and some luciferase expression in the tumour tissue. The systemic treatment using the HSV-tk/GCV approach showed a tumour growth reduction compared to the nontreated mice cohort. CONCLUSIONS These results are in good accordance with those obtained previously with PEG DNA LNCs in a human melanoma mouse model and highlight the potential use of GAL DNA MMS DOSP and PEG DNA LNCs as future therapeutics in glioma and other cancers.
Collapse
Affiliation(s)
- Stephanie David
- LUNAM Université - Equipe MINT: micro et nanomédecines biomimétiques, IBS-CHU, 4 rue Larrey, 49933, Angers Cedex 9, France
| | | | | | | | | | | | | | | | | |
Collapse
|
87
|
Morton SW, Poon Z, Hammond PT. The architecture and biological performance of drug-loaded LbL nanoparticles. Biomaterials 2013; 34:5328-35. [PMID: 23618629 DOI: 10.1016/j.biomaterials.2013.03.059] [Citation(s) in RCA: 74] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2013] [Accepted: 03/20/2013] [Indexed: 10/26/2022]
Abstract
Layer-by-Layer (LbL) nanoparticles are an emerging class of therapeutic carriers that afford precise control over key design parameters that facilitate improved drug and carrier pharmacokinetics, and enhanced molecular-targeting capabilities. This paper advances the development of these systems by establishing them as drug carriers, with the means to control drug release in a systemic environment and retard particle clearance from circulation, promoting improved biodistribution of the drug-containing system. Using dual-fluorescent tracking in vivo, this work establishes a robust means of screening libraries of LbL systems generated, affording simultaneous resolution over persistence and biodistribution of both the drug and carrier following systemic administration of a single particle formulation. Employing a PLGA drug-containing core as a substrate for LbL deposition, a range of coated systems were fabricated to investigate the abilities of these films to stabilize drug for delivery as well as to improve the pharmacokinetics of both the drug and carrier. Significant reductions in liver accumulation were observed for different formulations of the layered architectures within the first 30 min of systemic circulation. LbL architectures diminished liver localization of the surrogate drug, cardiogreen, by 10-25% ID/g relative to native PLGA nanoparticles and modulated carrier accumulation in the liver >50% ID/g. Further, enhanced persistence of the drug was observed with the coated systems, significantly increasing the drug half-life from 2 to 3 min for free drug and 1.87 h for the uncoated core to 4.17 h and 4.54 h for the coated systems. These systems provide an exciting, modular platform that improves the pharmacokinetic properties of the therapeutic, reduces bolus release of drug from nanoparticles, and enhances the safety and circulation half-life of the drug in vivo, proving them to be highly clinically-relevant and a promising approach for future development of molecularly-targeted and combination therapeutics.
Collapse
Affiliation(s)
- Stephen W Morton
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
| | | | | |
Collapse
|
88
|
Sun Q, Radosz M, Shen Y. Rational Design of Translational Nanocarriers. FUNCTIONAL POLYMERS FOR NANOMEDICINE 2013. [DOI: 10.1039/9781849737388-00032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- Qihang Sun
- Department of Chemical and Petroleum Engineering, Soft Materials Laboratory, University of WyomingLaramieWY 82071USA
| | - Maciej Radosz
- Department of Chemical and Petroleum Engineering, Soft Materials Laboratory, University of WyomingLaramieWY 82071USA
| | - Youqing Shen
- Center for Bionanoengineering and State Key Laboratory of Chemical Engineering, Department of Chemical and Biological Engineering, Zhejiang UniversityHangzhou 310027P. R.
| |
Collapse
|
89
|
Ozcelikkale A, Ghosh S, Han B. Multifaceted Transport Characteristics of Nanomedicine: Needs for Characterization in Dynamic Environment. Mol Pharm 2013; 10:2111-26. [PMID: 23517188 DOI: 10.1021/mp3005947] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Altug Ozcelikkale
- School
of Mechanical Engineering and ‡Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana,
United States
| | - Soham Ghosh
- School
of Mechanical Engineering and ‡Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana,
United States
| | - Bumsoo Han
- School
of Mechanical Engineering and ‡Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana,
United States
| |
Collapse
|
90
|
Singh AK, Pandey A, Tewari M, Kumar R, Sharma A, Pandey HP, Shukla HS. Prospects of nano-material in breast cancer management. Pathol Oncol Res 2013; 19:155-65. [PMID: 23435835 DOI: 10.1007/s12253-013-9609-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2011] [Accepted: 02/04/2013] [Indexed: 01/19/2023]
Abstract
Breast cancer evaluation and early diagnosis are core complexity worldwide and an ambiguity for scientists till date. Nano-materials are innovative tools for rapid diagnosis and therapy, which may induce an immense result in the field of oncology. Their exceptional size-dependent properties make them special and superior materials and quite indispensable in several fields of the human activities. The major obstacle in finding cure for malignant breast cancer is to increase in development of resistances for tumors to the therapeutic treatments. The widespread mammo-graph particle is being developed by nations to diagnosis disease in primitive stage to decline the mortality rates caused by breast carcinoma. The advancement of nano-particle based diagnostic tools facilitates in evaluation and provides encouraging development in breast cancer therapeutics. In this compact review, efforts have been made to compose the current advancements in the area of functional nano-particles. Furthermore, in vivo and in vitro applications of nano-materials in breast cancer management are also discussed.
Collapse
Affiliation(s)
- A K Singh
- Department of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India.
| | | | | | | | | | | | | |
Collapse
|
91
|
Benoit JP. [Conception and studies of micro and nanomedicines for brain applications]. Biol Aujourdhui 2013; 206:263-71. [PMID: 23419253 DOI: 10.1051/jbio/2012026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2012] [Indexed: 11/14/2022]
Abstract
As far as micromedicines are concerned, we are interested in the microencapsulation of recombinant proteins, to generate microcarriers upon which living cells can be adsorbed, a highly challenging technology. The whole system forms a Pharmacologically Active Microcarrier (PAM) to be used in cell therapy in the context of neurodegenerative diseases. More precisely, the PAMs are used for tissue engineering, they will increase cell survival time as well as the differentiation and integration of grafted cells following transplants in animals, these micromedicines can also activate the regenerative potential of adult stem cells such as the MIAMI cells. Within the domain of nanomedicines, we are pursuing the development of lipid nanocapsules that act as biomimetic nanovectors resembling lipoproteins. We are studying systematically the biodistribution profiles of these nanomedicines depending on their route of administration, local or systemic. In particular, we are trying to define the essential physicochemical parameters of these nanovectors that, after administration, control the targeting of tumours. In the same way, we are trying to understand how these nanomedicines cross biological barriers and how they interact with cells. In terms of preclinical applications, we are focusing on glioblastomas. The route of administration can be systemic or local. The most promising results in terms of survival of tumour-bearing animals were obtained by infusing radioactive nanocapsules intratumourally, in order to achieve an in-situ radiotherapy approach.
Collapse
Affiliation(s)
- Jean-Pierre Benoit
- Laboratoire Micro et Nanomédecines biomimétiques, INSERM U 1066, IBS-CHU, 4 rue Larrey, 49933 Angers Cedex 9, France.
| |
Collapse
|
92
|
Coles DJ, Rolfe BE, Boase NRB, Veedu RN, Thurecht KJ. Aptamer-targeted hyperbranched polymers: towards greater specificity for tumours in vivo. Chem Commun (Camb) 2013; 49:3836-8. [DOI: 10.1039/c3cc00127j] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
93
|
Sun Q, Radosz M, Shen Y. Challenges in design of translational nanocarriers. J Control Release 2012; 164:156-69. [DOI: 10.1016/j.jconrel.2012.05.042] [Citation(s) in RCA: 169] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2012] [Revised: 05/24/2012] [Accepted: 05/26/2012] [Indexed: 01/21/2023]
|
94
|
Chao X, Zhang Z, Guo L, Zhu J, Peng M, Vermorken AJM, Van de Ven WJM, Chen C, Cui Y. A novel magnetic nanoparticle drug carrier for enhanced cancer chemotherapy. PLoS One 2012; 7:e40388. [PMID: 23056167 PMCID: PMC3466217 DOI: 10.1371/journal.pone.0040388] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2012] [Accepted: 06/06/2012] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Magnetic nanoparticles (NPs) loaded with antitumor drugs in combination with an external magnetic field (EMF)-guided delivery can improve the efficacy of treatment and may decrease serious side effects. The purpose of this study was 1) to investigate application of PEG modified GMNPs (PGMNPs) as a drug carrier of the chemotherapy compound doxorubicin (DOX) in vitro; 2) to evaluate the therapeutic efficiency of DOX-conjugated PGMNPs (DOX-PGMNPs) using an EMF-guided delivery in vivo. METHODS First, DOX-PGMNPs were synthesized and the cytotoxicity of DOX-PGMNPs was assessed in vitro. Second, upon intravenous administration of DOX-PMGPNs to H22 hepatoma cell tumor-bearing mice, the DOX biodistribution in different organs (tissues) was measured. The antitumor activity was evaluated using different treatment strategies such as DOX-PMGPNs or DOX-PMGPNs with an EMF-guided delivery (DOX-PGMNPs-M). RESULTS The relative tumor volumes in DOX-PGMNPs-M, DOX-PGMNPs, and DOX groups were 5.46±1.48, 9.22±1.51, and 14.8±1.64, respectively (each p<0.05), following treatment for 33 days. The life span of tumor-bearing mice treated with DOX-PGMNPs-M, DOX-PGMNPs, and DOX were 74.8±9.95, 66.1±13.5, and 31.3±3.31 days, respectively (each p<0.05). CONCLUSION This simple and adaptive nanoparticle design may accommodate chemotherapy for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers in the near future.
Collapse
Affiliation(s)
- Xu Chao
- The College of Life Sciences, Northwest University, Xi'an, China
- The College of Basic Medical Science, Shaanxi University of Chinese Medicine, Xianyang, China
| | - Zhuoli Zhang
- Department of Radiology, Northwestern University, Chicago, Illinois, United States of America
| | - Lili Guo
- National Engineering Research Center for Miniaturized Detection Systems, Xi'an, China
| | - Jingjing Zhu
- Laboratory for Molecular Oncology, Department of Human Genetics, K.U. Leuven, Leuven, Belgium
| | - Mingli Peng
- National Engineering Research Center for Miniaturized Detection Systems, Xi'an, China
| | | | - Wim J. M. Van de Ven
- Laboratory for Molecular Oncology, Department of Human Genetics, K.U. Leuven, Leuven, Belgium
| | - Chao Chen
- The College of Life Sciences, Northwest University, Xi'an, China
- National Engineering Research Center for Miniaturized Detection Systems, Xi'an, China
| | - Yali Cui
- The College of Life Sciences, Northwest University, Xi'an, China
- National Engineering Research Center for Miniaturized Detection Systems, Xi'an, China
- * E-mail:
| |
Collapse
|
95
|
Mechanisms of transcellular transport of wheat germ agglutinin-functionalized polymeric nanoparticles in Caco-2 cells. Biomaterials 2012; 33:6769-82. [DOI: 10.1016/j.biomaterials.2012.05.066] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2012] [Accepted: 05/28/2012] [Indexed: 12/15/2022]
|
96
|
Silindir M, Özer AY, Erdoğan S. The use and importance of liposomes in positron emission tomography. Drug Deliv 2012; 19:68-80. [PMID: 22211758 DOI: 10.3109/10717544.2011.635721] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Among different imaging modalities, Positron Emission Tomography (PET) gained importance in routine hospital practice depending on ability to diagnose diseases in early stages and tracing of therapy by obtaining metabolic information. The combination of PET with Computed Tomography (CT) forms hybrid imaging modality that gives chance to obtain better images having higher resolution by fusing both functional and anatomical images in the same imaging modality at the same time. Therefore, better contrast agents are essentially needed. The advance in research about developing drug delivery systems as specific nanosized targeted systems gained an additional importance for obtaining better diagnosis and therapy of different diseases. Liposomes appear to be more attractive drug delivery systems in delivering either drugs or imaging ligands to target tissue or organ of diseases with higher accumulation by producing in nano-scale, long circulating by stealth effect and specific targeting by modifying with specific ligands or markers. The combination of positron emitting radionuclides with liposomes are commonly in research level nowadays and there is no commercially available liposome formulation for PET imaging. However by conjugating positron emitter radionuclide with liposomes can form promising diagnostic agents for improved diagnosis and following up treatments by increasing image signal/contrast in the target tissue in lower concentrations by specific targeting as the most important advantage of liposomes. More accurate and earlier diagnosis of several diseases can be obtained even in molecular level with the use of stable and effectively radiolabeled molecular target specific nano sized liposomes with longer half-lived positron emitting radionuclides.
Collapse
Affiliation(s)
- Mine Silindir
- Department of Radiopharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
| | | | | |
Collapse
|
97
|
Li Y, Li Z, Wang X, Liu F, Cheng Y, Zhang B, Shi D. In vivo cancer targeting and imaging-guided surgery with near infrared-emitting quantum dot bioconjugates. Theranostics 2012; 2:769-76. [PMID: 22916076 PMCID: PMC3425123 DOI: 10.7150/thno.4690] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2012] [Accepted: 07/02/2012] [Indexed: 01/06/2023] Open
Abstract
Early detection and subsequent complete surgical resection are among the most efficient methods for treating cancer. However, low detection sensitivity and incomplete tumor resection are two challenging issues. Nanoparticle-based imaging-guided surgery has proven promising for cancer-targeted imaging and subsequent debulking surgery. Particularly, the use of near infrared (NIR) fluorescent probes such as NIR quantum dots (QDs) allows deep penetration and high sensitivity for tumor detection. In this study, NIR-emitting CdTe QDs (maximum fluorescence emission peak at 728 nm) were synthesized with a high quantum yield (QY) of 38%. The tumor-specific QD bioconjugates were obtained by attaching cyclic Arg-Gly-Asp peptide (cRGD) to the surface of synthesized QDs, and then injected into U87 MG tumor-bearing mice via tail veins for tumor-targeted imaging. The tumor and its margins were visualized and distinguished by NIR QD bioconjugates, and tumor resection was successfully accomplished via NIR guidance using a Fluobeam-700 NIR imaging system. Our work indicates that the synthesized tumor-specific NIR QDs hold great promise as a potential fluorescent indicator for intraoperative tumor imaging.
Collapse
|
98
|
Lainé AL, Passirani C. Novel metal-based anticancer drugs: a new challenge in drug delivery. Curr Opin Pharmacol 2012; 12:420-6. [DOI: 10.1016/j.coph.2012.04.006] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2012] [Revised: 04/06/2012] [Accepted: 04/21/2012] [Indexed: 02/05/2023]
|
99
|
Şimşek S, Eroğlu H, Kurum B, Ulubayram K. Brain targeting of Atorvastatin loaded amphiphilic PLGA-b-PEG nanoparticles. J Microencapsul 2012; 30:10-20. [DOI: 10.3109/02652048.2012.692400] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|
100
|
Cheng L, Yang K, Chen Q, Liu Z. Organic stealth nanoparticles for highly effective in vivo near-infrared photothermal therapy of cancer. ACS NANO 2012; 6:5605-13. [PMID: 22616847 DOI: 10.1021/nn301539m] [Citation(s) in RCA: 305] [Impact Index Per Article: 25.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
In recent years, a wide range of near-infrared (NIR) light absorbing nanomaterials, mostly inorganic ones, have been developed for photothermal therapy (PTT) of cancer. In this work, we develop a novel organic PTT agent based on poly-(3,4-ethylenedioxythiophene):poly(4-styrenesulfonate) (PEDOT:PSS), a conductive polymer mixture with strong NIR absorbance, for in vivo photothermal treatment of cancer. After being layer-by-layer coated with charged polymers and then conjugated with branched polyethylene glycol (PEG), the obtained PEDOT:PSS-PEG nanoparticles are highly stable in the physiological environment and exhibit a stealth-like behavior after intravenous injection with a long blood circulation half-life. As a result, an extremely high in vivo tumor uptake of PEDOT:PSS-PEG attributed to the tumor-enhanced permeability and retention effect is observed. We further use PEDOT:PSS-PEG as a PTT agent for in vivo cancer treatment and realize excellent therapeutic efficacy in a mouse tumor model under NIR light irradiation at a low laser power density. Comprehensive blood tests and careful histological examination reveal no apparent toxicity of PEDOT:PSS-PEG to mice at our treated dose within 40 days. To our best knowledge, this work is the first to use systemically administrated conductive polymer nanoparticles for highly effective in vivo PTT treatment in animals and encourages further explorations of those organic nanomaterials for cancer theranostic applications.
Collapse
Affiliation(s)
- Liang Cheng
- Functional Nano & Soft Materials Laboratory (FUNSOM) and Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou, Jiangsu 215123, China
| | | | | | | |
Collapse
|